Company
Recce Pharmaceuticals Ltd
ASX:RCE
Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
169 stories · page 7 of 9
Recce Pharmaceuticals RECCE327 treatment ‘significantly’ reduces COVID-19 in hamsters
“The data received from Viroclinics indicates the potential of R327’s capabilities as a treatment for viral infections,” said CEO James Graham.
Recce Pharmaceuticals accelerates and expands clinical programs across portfolio
“With good safety and encouraging signs of efficacy, we look ahead to new indications that can best adapt to physician and patient needs. We have therefore established an ambitious development plan, aiming to get new anti-infective therapie
Recce Pharmaceuticals to deliver opening R&D address at World Anti-Microbial Resistance Congress
There has been a lack of innovation in new antibiotic drug development, with almost every antibiotic on the market based on scientific discoveries from more than 30 years ago.
Recce Pharmaceuticals appoints Dr John Prendergast as executive chair
“Bringing a depth of knowledge and well recognised capability as a veteran in biotechnology and international capital markets, we greatly look forward to his [Dr Prendergast's] continued contributions over the time ahead," CEO James Graham
Recce Pharmaceuticals appoints Alistair McKeough as non-executive director
Recce chairman Dr John Prendergast said: “He knows the company well, is excited about the future for Recce and brings deep insights into Australia’s financial, corporate and regulatory environments.”
Recce Pharmaceuticals doses anti-infective trial’s seventh cohort with no serious adverse effects
Recce 327 is allegedly the only clinical-stage new class of antibiotic in the world being developed for sepsis — the largest unmet medical need in human health.
Recce Pharmaceuticals appoints scientific adviser to fulltime position as it develops pipeline tackling antibiotic resistance
“I am delighted to join the Recce team and look forward to the time ahead in addressing the global health problem of antibiotic-resistant superbugs and emerging viral pathogens,” Dr Philip Sutton said.
ASX lifts after seven days, but recession fears loom as inflation gets worse
Treasurer Jim Chalmers says inflation will get worse before it gets better as RBA chair calms the waters over recession fears.
Recce Pharmaceuticals jumps on positive safety data during trial dosing participants with anti-infective
According to a global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
Recce Pharmaceuticals fields positive safety data from fifth cohort of phase 1 trial for synthetic anti-infective asset
“This data builds on previous cohorts and validates RECCE® 327’s compelling safety and tolerability profile, with the potential to serve as a solution for patients with sepsis,” says CEO James Graham.
Recce Pharmaceuticals progresses to 2,000mg dosing levels
James Graham, Chief Executive Officer of Recce Pharmaceuticals Ltd said, “Recommendation to commence ‘high dosing’ at 2,000mg – a 40-fold increase from initial dosing of 50mg in Cohort 1 by the independent safety committee is a welcome vali
Recce Pharmaceuticals granted anti-viral patent in Hong Kong for RECCE Anti-Infectives
“This newly granted patent by the Hong Kong Special Administrative Region of the People's Republic of China is another endorsement for our commercial and clinical development strategy highlighting the potential of our Australian anti-infect
Recce Pharmaceuticals dosing trial for next-generation antibiotic indicates good safety and tolerability
The company has recorded positive safety data from the fourth cohort of its Phase 1 clinical trial evaluating healthy participants intravenously dosed with anti-infective candidate RECCE® 327.
Recce Pharmaceuticals granted A$3 million boost for infectious disease R&D
Recce Pharmaceuticals CEO James Graham welcomes the rebate: “We appreciate the continued support and acknowledgement by the Australian Government for the critical work undertaken in our infectious disease programs. This non-dilutionary cash
Recce Pharmaceuticals sees safety committee clear next dose in Phase I Clinical Study of sepsis drug RECCE® 327
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.